



## New Advances in the Treatment of Resectable Non-small Cell Lung Cancer

Guest Editors:

**Dr. Francesco Facciolo**

Thoracic Surgery Department,  
IRCCS Regina Elena National  
Cancer Institute, 00144 Rome,  
Italy

**Dr. Luca Bertolaccini**

Department of Thoracic Surgery -  
IEO, European Institute of  
Oncology IRCCS, Milan, IT, Italy

**Dr. Federico Cappuzzo**

Medical Oncology, IRCCS Regina  
Elena National Cancer Institute,  
00144 Rome, Italy

Deadline for manuscript  
submissions:

**closed (15 September 2023)**

### Message from the Guest Editors

Despite the evolution in non-small cell lung cancer treatment, the overall prognosis is still poor. In this context, lobectomy and radical lymphadenectomy remain the cornerstone of surgical treatment of resectable NSCLC. One of the most important prognostic factors remains the presence of lymph node involvement, particularly the presence of mediastinal nodal involvement. Furthermore, correct intraoperative staging is mandatory to reach an actual pathological status of the disease. The recent approval of Osimertinib for resected EGFR-mutated NSCLC in an adjuvant setting has led to the hypothesis that other targeted therapies used in metastatic patients can also lead to improved early-stage outcomes of NSCLC. Indeed, in addition to surgical treatment, some target therapies are being tested in adjuvant settings with promising outcomes. For this Special Issue, we welcome reviews and original research focusing on recent advancements in the preoperative staging, the surgical resection of NSCLC, the role of the new medications approved as adjuvant and neoadjuvant therapies, economic evaluation, and cost-effectiveness.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Shahid Ahmed

1. College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada

2. Saskatchewan Cancer Agency, Saskatoon Cancer Center, Saskatoon, SK S7N5H5, Canada

## Message from the Editor-in-Chief

I am honored and enthusiastic to serve as Editor-in-Chief of *Current Oncology*. Since its establishment in 1994, *Current Oncology* has been playing an important role in the advancement of cancer care by disseminating new knowledge in the cancer care continuum. *Current Oncology* is affiliated with several key cancer societies and provides a global platform to share scientific progress in oncology. We strive for high standards and work together to maintain a rigorous and unbiased peer review process to publish high-quality articles. We have an outstanding editorial team which is committed to the success of *Current Oncology*.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **MEDLINE**, **PMC**, **Embase**, and **other databases**.

**Journal Rank:** JCR - Q2 (Oncology)

## Contact Us

*Current Oncology* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/currenconcol](http://mdpi.com/journal/currenconcol)  
[currentoncology@mdpi.com](mailto:currentoncology@mdpi.com)  
[X@CurrentOncology](https://twitter.com/CurrentOncology)